[Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
Koizumi
Masahiro
M
Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine.
Fukagawa
Masafumi
M
D000924:Anticholesteremic Agents; D001798:Blood Proteins / Q000378:metabolism; D002114:Calcinosis / Q000188:drug therapy* / Q000209:etiology; D002614:Chelating Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002908:Chronic Disease; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology; D054559:Hyperphosphatemia / Q000150:complications* / Q000188:drug therapy*; D007674:Kidney Diseases / Q000150:complications*; D011073:Polyamines / Q000494:pharmacology / Q000627:therapeutic use*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D000069603:Sevelamer; D014652:Vascular Diseases / Q000188:drug therapy* / Q000209:etiology; D060749:alpha-2-HS-Glycoprotein
C556354:AHSG protein, human; D000924:Anticholesteremic Agents; D001798:Blood Proteins; D002614:Chelating Agents; D011073:Polyamines; D060749:alpha-2-HS-Glycoprotein; D000069603:Sevelamer